Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 3, 2008, Pages 323-330

  Wagenblast, Jens ^a   Hambek, Markus ^a   Baghi, Mehran ^a   Gstöttner, Wolfgang ^a   Strebhardt, Klaus ^a   Ackermann, Hanns ^a   Knecht, Rainald ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Apoptosis; Bortezomib; Cisplatin; Docetaxel; Growth inhibition; Squamous cell head and neck carcinoma cell lines

Indexed keywords

BORTEZOMIB; CISPLATIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MONOTHERAPY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HEAD AND NECK NEOPLASMS; HUMANS; PYRAZINES; TAXOIDS;

EID: 38649116043     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0287-9     Document Type: Article

References (27)

1. Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4(5):349-360
2. An J, Sun YP et al (2003) Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 9(12):4537-4545
3. Bhurgri Y, Bhurgri A et al (2006) Epidemiological review of head and neck cancers in Karachi. Asian Pac J Cancer Prev 7(2):195-200
4. Burger AM, Seth AK (2004) The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 40(15):2217-2229
5. Ciechanover A, Schwartz AL (1998) The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci U S A 95(6):2727-2730
6. Clavel M, Vermorken JB et al (1994) Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5(6):521-6
7. Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29(Suppl 1):21-31
8. Fanucchi MP, Fossella FV et al (2006) Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24(31):5025-5033
9. Forastiere AA, Metch B et al (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10(8):1245-1251
10. Forastiere AA, Leong T et al (2001) Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 19(4):1088-1095
11. Fribley A, Zeng Q et al (2004) Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24(22):9695-9704
12. Fribley AM, Evenchik B et al (2006) Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 281(42):31440-31447
13. Ishii Y, Waxman S et al (2007) Targeting the ubiquitin-proteasome pathway in cancer therapy. Anticancer Agents Med Chem 7(3):359-365
14. Jacobs C, Lyman G et al (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10(2):257-263
15. Kohno N (2005) The role of taxanes for head and neck cancer. Gan To Kagaku Ryoho 32(13):2035-2039
16. Lenz HJ (2003) Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29(Suppl 1):41-48
17. Ling YH, Liebes L et al (2003) Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9(3):1145-1154
18. Ling YH, Liebes L et al (2002) PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1(10):841-849
19. Messersmith WA, Baker SD et al (2006) Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12(4):1270-1275
20. Mortenson MM, Schlieman MG et al (2004) Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 54(4):343-353
21. Nawrocki ST, Sweeney-Gotsch B et al (2004) The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 3(1):59-70
22. Roccaro AM, Hideshima T et al (2006) Bortezomib as an antitumor agent. Curr Pharm Biotechnol 7(6):441-448
23. Sankaranarayanan R, Masuyer E et al (1998) Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res 18(6B):4779-4786
24. Schenkein DP (2004) Use of proteasome inhibition in the treatment of lung cancer. Clin Lung Cancer 6(Suppl 2):S89-S96
25. Schrijvers D, Johnson J et al (1998) Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. J Clin Oncol 16(3):1054-1059
26. Tumino R, Vicario G (2004) Head and neck cancers: oral cavity, pharynx, and larynx. Epidemiol Prev 28(2 Suppl):28-33
27. Yang Y, Ikezoe T et al (2004) Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 95(2):176-180